Literature DB >> 22902505

The metabolite 3-hydroxiglutaric acid effectively reduces glioblastoma growth in vivo by affecting the structural integrity of tumor vasculature.

Leticia Oliveira-Ferrer1, Jasmin Wellbrock, Melanie Braig, Marianne Klokow, Jessica Hauschild, Carsten Bokemeyer, Walter Fiedler, Suleyman Ergun, Gunter Schuch.   

Abstract

3-Hydroxiglutaric acid (3-OH-GA) is a disease-specific metabolite that accumulates in tissues and body fluids of patients with Glutaric aciduria type I (GAI) and has been associated with vascular abnormalities in these kindreds. Here, we demonstrate that 3-OH-GA also affects the integrity of tumor vessels leading to tumor growth inhibition in a subcutaneous model of human glioblastoma multiforme (GBM). This effect correlated with a marked decrease of VE-Cadherin expression in endothelium of 3-OH-GA-treated tumors. Furthermore, in vitro observations indicated also a direct effect of 3-OH-GA in glioma cells that showed defective mitosis and significant proliferation inhibition. In summary, the GAI-specific metabolite 3-OH-GA significantly inhibited growth of GBM xenografts by affecting the structural integrity of tumor blood vessels and in addition by causing defective mitosis and proliferation inhibition of tumor cells.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22902505     DOI: 10.1016/j.canlet.2012.08.002

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  2 in total

1.  Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway.

Authors:  Leticia Oliveira-Ferrer; Jasmin Wellbrock; Udo Bartsch; Eva Maria Murga Penas; Jessica Hauschild; Marianne Klokow; Carsten Bokemeyer; Walter Fiedler; Gunter Schuch
Journal:  Mol Cancer       Date:  2013-11-20       Impact factor: 27.401

2.  c-FOS suppresses ovarian cancer progression by changing adhesion.

Authors:  L Oliveira-Ferrer; K Rößler; V Haustein; C Schröder; D Wicklein; D Maltseva; N Khaustova; T Samatov; A Tonevitsky; S Mahner; F Jänicke; U Schumacher; K Milde-Langosch
Journal:  Br J Cancer       Date:  2013-12-05       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.